Table 1.
Basic information on the surgical treatment results of MRONJ patients caused by anti-resorptive drugs and anti-resorptive drugs plus anti-angiogenic drugs
| Variable | Anti-resorptivedrug group (n = 74) | Anti-resorptive drug + anti-angiogenic drug group (n = 31) | P |
|---|---|---|---|
| Gender | |||
| Male | 28 (37.84) | 21 (67.74) | 0.006‡ |
| Female | 46 (62.16) | 10 (32.26) | |
| Average age ± SD (year) | 65.18 ± 10.34 | 61.32 ± 5.92 | 0.061* |
| Duration of anti-resorptive drugs in months ± SD | 37.09 ± 28.91 | 26.61 ± 15.25 | 0.005* |
| Anti-angiogenic medications | |||
| Suntinib | NA | 9 (29.03) | NA |
| Bevacizumab | 10 (32.26) | ||
| Anlotinib | 5 (16.13) | ||
| others | 7 (22.58) | ||
| Underlying disease | |||
| Osteoporosis | 11 (14.86) | 0 (0.00) | NA |
| Breast cancer | 25 (33.78) | 4 (12.90) | |
| Lung cancer | 15 (20.27) | 17 (54.84) | |
| Kidney cancer | 0 (0.00) | 8 (25.81) | |
| Prostate cancer | 15 (20.27) | 0 (0.00) | |
| Multiple myeloma | 7 (9.46) | 0 (0.00) | |
| Others | 1 (1.35) | 2 (6.45) | |
| MRONJ location | |||
| Maxilla | 24 (32.43) | 11 (35.48) | 0.466‡ |
| Mandible | 50 (67.57) | 20 (64.52) | |
| Clinical symptom | |||
| Jaw exposure | 31 (41.89) | 22(70.97) | 0.010 |
| Skin or mucosa fistula | 43 (58.11) | 9 (29.03) | |
| MRONJ stage | |||
| 1 | 16 (21.62) | 2 (6.45) | 0.031‡ |
| 2 | 43 (58.11) | 16 (51.61) | |
| 3 | 15 (20.27) | 13 (41.94) | |
| Surgical methods | |||
| Marginal osteotomy | 64 (86.49) | 24 (77.42) | 0.259‡ |
| Segment osteotomy | 10 (13.51) | 7 (22.58) | |
| Treatment results | |||
| Healed | 52 (70.27) | 12 (38.71) | 0.004‡ |
| Non-healing | 22 (29.73) | 19 (61.29) | |
Data presented as n (%), unless otherwise noted. MRONJ, medication-related osteonecrosis of the jaw; SD, standard deviation
* Independent-sample t-test
‡χ2 test